English
This article is from Journal of Molecular and Cellular Cardiology , volume 72 . Abstract Lower heart rate is associated with better survival in patients with multiple organ dysfunction syndrome (MODS), a disease mostly caused by sepsis. The benefits of heart rate reduction by ivabradine during MODS are currently being investigated in the MODIfY clinical trial. Ivabradine is a selective inhibitor of the pacemaker current If and since If is impaired by lipopolysaccharide (LPS, endotoxin), a trigger of sepsis, we aimed to explore If blocking potency of ivabradine under elevated endotoxin levels in human atrial cardiomyocytes. Treatment of myocytes with S-LPS (containing the lipid A moiety, a core oligosaccharide and an O-polysaccharide chain) but not R595 (an O-chain lacking LPS-form) caused If inhibition under acute and chronic septic conditions. The specific interaction of S-LPS but not R595 to pacemaker channels HCN2 and HCN4 proves the necessity of O-chain for S-LPS–HCN interaction. The efficacy of ivabradine to block If was reduced under septic conditions, an observation that correlated with lower intracellular ivabradine concentrations in S-LPS- but not R595-treated cardiomyocyt
Sign in with your free account to read, download EPUBs or listen.
Ebook · If blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes. · Scheruebel, Susanne, Koyani, Chintan N., Hallstrom, Seth, Lang, Petra, Platzer, Dieter, Machler, Heinrich, Lohner, Karl, Malle, Ernst · Internet Archive